Cancer Research AACR Membership  Metabolism
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Eisenmann, K. M.
Right arrow Articles by Koo, H.-M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Eisenmann, K. M.
Right arrow Articles by Koo, H.-M.
[Cancer Research 63, 8330-8337, December 1, 2003]
© 2003 American Association for Cancer Research


Regular Articles

Mitogen-Activated Protein Kinase Pathway-Dependent Tumor-Specific Survival Signaling in Melanoma Cells through Inactivation of the Proapoptotic Protein Bad

Kathryn M. Eisenmann, Matthew W. VanBrocklin, Nancy A. Staffend, Susan M. Kitchen and Han-Mo Koo

Laboratory of Cancer Pharmacogenetics, Van Andel Research Institute, Grand Rapids, Michigan

Mitogen-activated protein kinase (MAPK) signaling regulates fundamental cellular functions including proliferation, differentiation, and survival. We have demonstrated previously that inhibiting MAPK signaling induces apoptosis in melanoma cells but not in normal melanocytes, suggesting that the MAPK pathway propagates essential survival signals in melanoma cells. Here, we report that the 90-kDa ribosomal S6 kinase (RSK), a downstream effector in the MAPK signaling cascade, phosphorylates and inactivates the Bcl-2 homology 3-only proapoptotic protein Bad, thereby mediating a MAPK-dependent tumor-specific survival signal in melanoma cells. The MAPK kinase (MEK)/extracellular signal-regulated kinase (ERK)/RSK MAPK signaling module is constitutively hyperactivated, and Bad is maintained in its inactive state by phosphorylation at Ser75 in a MEK/ERK/RSK-dependent manner in melanoma cells. In contrast, in normal melanocytes, Bad is highly phosphorylated at multiple residues (Ser75, Ser99, and Ser118) in a MAPK pathway-independent manner. Importantly, ectopic expression of a constitutively activated RSK mutant abrogates Bad activation and renders melanoma cells resistant to apoptosis induced by a MEK inhibitor. Furthermore, overexpressing alanine-substituted (S75A) Bad further sensitizes melanoma cells to MEK inhibitor-induced apoptosis. Our results suggest that the MAPK pathway mediates melanoma-specific survival signaling by differentially regulating RSK-mediated phosphorylation of the proapoptotic protein Bad and may present potentially selective therapeutic targets for the treatment of melanomas.




This article has been cited by other articles:


Home page
Proc. Natl. Acad. Sci. USAHome page
M. D. Larrea, F. Hong, S. A. Wander, T. G. da Silva, D. Helfman, D. Lannigan, J. A. Smith, and J. M. Slingerland
RSK1 drives p27Kip1 phosphorylation at T198 to promote RhoA inhibition and increase cell motility
PNAS, June 9, 2009; 106(23): 9268 - 9273.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
M. W. VanBrocklin, M. Verhaegen, M. S. Soengas, and S. L. Holmen
Mitogen-Activated Protein Kinase Inhibition Induces Translocation of Bmf to Promote Apoptosis in Melanoma
Cancer Res., March 1, 2009; 69(5): 1985 - 1994.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
K.-W. Lee, S. G. Kim, H.-P. Kim, E. Kwon, J. You, H.-J. Choi, J.-H. Park, B.-C. Kang, S.-A. Im, T.-Y. Kim, et al.
Enzastaurin, a Protein Kinase C{beta} Inhibitor, Suppresses Signaling through the Ribosomal S6 Kinase and Bad Pathways and Induces Apoptosis in Human Gastric Cancer Cells
Cancer Res., March 15, 2008; 68(6): 1916 - 1926.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
Y.-H. Liao, S.-M. Hsu, and P.-H. Huang
ARMS Depletion Facilitates UV Irradiation Induced Apoptotic Cell Death in Melanoma
Cancer Res., December 15, 2007; 67(24): 11547 - 11556.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
C. C. Jiang, L. H. Chen, S. Gillespie, Y. F. Wang, K. A. Kiejda, X. D. Zhang, and P. Hersey
Inhibition of MEK Sensitizes Human Melanoma Cells to Endoplasmic Reticulum Stress-Induced Apoptosis
Cancer Res., October 15, 2007; 67(20): 9750 - 9761.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
Y. F. Wang, C. C. Jiang, K. A. Kiejda, S. Gillespie, X. D. Zhang, and P. Hersey
Apoptosis Induction in Human Melanoma Cells by Inhibition of MEK Is Caspase-Independent and Mediated by the Bcl-2 Family Members PUMA, Bim, and Mcl-1
Clin. Cancer Res., August 15, 2007; 13(16): 4934 - 4942.
[Abstract] [Full Text] [PDF]


Home page
Arch Otolaryngol Head Neck SurgHome page
Y. C. Henderson, M. J. Fredrick, and G. L. Clayman
Differential Responses of Human Papillary Thyroid Cancer Cell Lines Carrying the RET/PTC1 Rearrangement or a BRAF Mutation to MEK1/2 Inhibitors
Arch Otolaryngol Head Neck Surg, August 1, 2007; 133(8): 810 - 815.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
B. R. Davies, A. Logie, J. S. McKay, P. Martin, S. Steele, R. Jenkins, M. Cockerill, S. Cartlidge, and P. D. Smith
AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models
Mol. Cancer Ther., August 1, 2007; 6(8): 2209 - 2219.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
B. Escudier, N. Lassau, E. Angevin, J. C. Soria, L. Chami, M. Lamuraglia, E. Zafarana, V. Landreau, B. Schwartz, E. Brendel, et al.
Phase I Trial of Sorafenib in Combination with IFN {alpha}-2a in Patients with Unresectable and/or Metastatic Renal Cell Carcinoma or Malignant Melanoma
Clin. Cancer Res., March 15, 2007; 13(6): 1801 - 1809.
[Abstract] [Full Text] [PDF]


Home page
Physiol. Rev.Home page
G. Kroemer, L. Galluzzi, and C. Brenner
Mitochondrial Membrane Permeabilization in Cell Death
Physiol Rev, January 1, 2007; 87(1): 99 - 163.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
M. Verhaegen, J. A. Bauer, C. Martin de la Vega, G. Wang, K. G. Wolter, J. C. Brenner, Z. Nikolovska-Coleska, A. Bengtson, R. Nair, J. T. Elder, et al.
A Novel BH3 Mimetic Reveals a Mitogen-Activated Protein Kinase-Dependent Mechanism of Melanoma Cell Death Controlled by p53 and Reactive Oxygen Species
Cancer Res., December 1, 2006; 66(23): 11348 - 11359.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
A. J. Robinson-White, W. W. Leitner, E. Aleem, P. Kaldis, I. Bossis, and C. A. Stratakis
PRKAR1A Inactivation Leads to Increased Proliferation and Decreased Apoptosis in Human B Lymphocytes
Cancer Res., November 1, 2006; 66(21): 10603 - 10612.
[Abstract] [Full Text] [PDF]


Home page
Mol Cancer ResHome page
M. Kono, I. S. Dunn, P. J. Durda, D. Butera, L. B. Rose, T. J. Haggerty, E. M. Benson, and J. T. Kurnick
Role of the Mitogen-Activated Protein Kinase Signaling Pathway in the Regulation of Human Melanocytic Antigen Expression
Mol. Cancer Res., October 1, 2006; 4(10): 779 - 792.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
D. C. Birle and D. W. Hedley
Signaling interactions of rapamycin combined with erlotinib in cervical carcinoma xenografts.
Mol. Cancer Ther., October 1, 2006; 5(10): 2494 - 2502.
[Abstract] [Full Text] [PDF]


Home page
Genes Dev.Home page
L. Chin, L. A. Garraway, and D. E. Fisher
Malignant melanoma: genetics and therapeutics in the genomic era.
Genes & Dev., August 15, 2006; 20(16): 2149 - 2182.
[Abstract] [Full Text] [PDF]


Home page
Mol Cancer ResHome page
W. Jia, V. L. Hegde, N. P. Singh, D. Sisco, S. Grant, M. Nagarkatti, and P. S. Nagarkatti
{Delta}9-Tetrahydrocannabinol-Induced Apoptosis in Jurkat Leukemia T Cells Is Regulated by Translocation of Bad to Mitochondria
Mol. Cancer Res., August 1, 2006; 4(8): 549 - 562.
[Abstract] [Full Text] [PDF]


Home page
J. Neurosci.Home page
K. N. McFarland, S. R. Wilkes, S. E. Koss, K. S. Ravichandran, and J. W. Mandell
Neural-specific inactivation of ShcA results in increased embryonic neural progenitor apoptosis and microencephaly.
J. Neurosci., July 26, 2006; 26(30): 7885 - 7897.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
U. K. Misra, R. Deedwania, and S. V. Pizzo
Activation and Cross-talk between Akt, NF-{kappa}B, and Unfolded Protein Response Signaling in 1-LN Prostate Cancer Cells Consequent to Ligation of Cell Surface-associated GRP78
J. Biol. Chem., May 12, 2006; 281(19): 13694 - 13707.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
D. J. Panka, M. B. Atkins, and J. W. Mier
Targeting the mitogen-activated protein kinase pathway in the treatment of malignant melanoma.
Clin. Cancer Res., April 1, 2006; 12(7): 2371s - 2375s.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
D. J. Panka, W. Wang, M. B. Atkins, and J. W. Mier
The Raf Inhibitor BAY 43-9006 (Sorafenib) Induces Caspase-Independent Apoptosis in Melanoma Cells
Cancer Res., February 1, 2006; 66(3): 1611 - 1619.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
S. S. Sridhar, D. Hedley, and L. L. Siu
Raf kinase as a target for anticancer therapeutics
Mol. Cancer Ther., April 1, 2005; 4(4): 677 - 685.
[Abstract] [Full Text] [PDF]


Home page
Integr Cancer TherHome page
M. F. McCarty
Targeting Multiple Signaling Pathways as a Strategy for Managing Prostate Cancer: Multifocal Signal Modulation Therapy
Integr Cancer Ther, December 1, 2004; 3(4): 349 - 380.
[Abstract] [PDF]


Home page
Mol. Cell. Biol.Home page
B. Zhang, Y. Zhang, and E. Shacter
Rac1 Inhibits Apoptosis in Human Lymphoma Cells by Stimulating Bad Phosphorylation on Ser-75
Mol. Cell. Biol., July 15, 2004; 24(14): 6205 - 6214.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2003 by the American Association for Cancer Research.